<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536052</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00141401</org_study_id>
    <nct_id>NCT03536052</nct_id>
  </id_info>
  <brief_title>Ablation at Virtual-hEart pRedicted Targets for VT</brief_title>
  <acronym>AVERT-VT</acronym>
  <official_title>Ablation at Virtual-hEart pRedicted Targets for VT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test the efficacy of the new imaging/simulation (&quot;virtual&#xD;
      heart&quot;) approach for determining the optimal ablation sites in patients with VT, which render&#xD;
      post-infarction VT non-inducible. The study will test both the acute outcome of the ablation&#xD;
      procedure, and the effect the use of the predicted targets has upon procedure time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular Tachycardia Inducibility</measure>
    <time_frame>time of procedure</time_frame>
    <description>Following ablation, inducibility of VT will be determined using programmed electrical stimulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from Ventricular Tachycardia</measure>
    <time_frame>1 year</time_frame>
    <description>Long term Freedom of Spontaneous Ventricular Tachycardia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Virtual Heart Guided Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtual Heart Guided Ablation</intervention_name>
    <description>If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.</description>
    <arm_group_label>Virtual Heart Guided Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible patients must be at least 18 years old at the time of enrollment.&#xD;
&#xD;
          -  A Pre-Op cardiac MRI including late gadolinium enhancement (LGE) must be performed&#xD;
             prior to ablation. As Johns Hopkins University (JHU) performs MRIs with implantable&#xD;
             cardioverter defibrillator (ICD) or pacemaker implanted, patients with these devices&#xD;
             may be enrolled.&#xD;
&#xD;
          -  Eligible patients must suffer from VT, thought to be secondary to structural heart&#xD;
             disease (scarring).&#xD;
&#xD;
          -  Eligible patients must be determined to be suitable candidates for ablation to treat&#xD;
             VT by their cardiologist and/or electrophysiologists regardless of this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Glomerular Filtration Rate (GFR) &lt; 30 mL/min should not be enrolled in&#xD;
             the study due to the use of intravenous gadolinium as an MRI contrast agent&#xD;
&#xD;
          -  If a pre-procedure MRI cannot or likely will not be performed for any reason (such as&#xD;
             claustrophobia), the patient must be excluded.&#xD;
&#xD;
          -  Pregnant women may not participate in the study because gadolinium MRI contrast is&#xD;
             contraindicated in these patients.&#xD;
&#xD;
          -  Any subject that, during the course of the pre-procedure imaging, is discovered to&#xD;
             have VT not related to scarring, he/she must be de-enrolled from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan Chrispin, MD</last_name>
    <phone>410-614-6076</phone>
    <email>chrispin@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Chrispin, MD</last_name>
      <phone>410-614-6076</phone>
      <email>chrispin@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

